NCT06841406招募中4 期
Budesonide As a Treatment for Low-grade Duodenal Inflammation in Functional Dyspepsia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Effect of Budesonide on the reduction of the number of eosinophils on duodenal biopsies in patients with functional dyspepsia
研究概览
简要总结
This clinical study is being conducted to evaluate the investigational drug, Budesonide, for the treatment of functional dyspepsia. The goal of this study is to learn more about the effect of Budesonide on patients with functional dyspepsia. Budesonide is a well-known and commonly used drug, and is part of the recommended therapy for patients with inflammatory bowel diseases (Crohn's disease or ulcerative colitis). It is also used as inhalation therapy for respiratory conditions such as asthma and COPD. However, the effect of Budesonide in patients with functional dyspepsia is still unknown. In patients with functional dyspepsia, an increased presence of inflammatory cells has been observed in the duodenum. Budesonide may reduce inflammatory responses.
Therefore, with this study, the investigators aim to investigate primarily:
- Whether Budesonide has an effect on the inflammatory cells observed in functional dyspepsia.
- Whether the symptoms of patients with functional dyspepsia improve during and after taking Budesonide.
- Whether inflammatory cells could be the cause of symptoms in functional dyspepsia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Functional dyspepsia (subtype postprandial distress syndrome) as per Rome IV diagnostic criteria
- •Symptom characteristics of dyspepsia (upper gastrointestinal symptoms occurring in the last 3 months and meal related)
- •Negative endoscopy (maximum 12 months old)
- •Patients must provide witnessed written informed consent prior to any study procedures being performed
- •Patients aged between 18 and 70 years inclusive
- •Male or female patients
- •Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Highly effective birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses
- •Subjects who are capable to understand the study and the questionnaires, and to comply with the study requirements
排除标准
- •Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for entry into the study
- •Patients with any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years
- •Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) or of gastro-esophageal reflux disease (GERD)
- •Presence of diabetes mellitus, celiac disease (diagnosed with presence of anti-tissue transglutaminase antibodies and anti-gliadin antibodies or via duodenal biopsies), lupus, scleroderma or other systemic auto-immune disease
- •Patients with eosinophilic esophagitis or eosinophilic gastroenteritis
- •Active H. Pylori infection (or < 6 months after eradication)
- •Organic gastro-intestinal disease of history of gastrointestinal surgery other than appendectomy
- •Known impaired liver dysfunction
- •Drugs altering gastric emptying, anti-inflammatory drugs, acid suppressive drugs or some drugs altering the CYP3A4 metabolism
- •Major change in diet last 3 months
- •Females who are pregnant or lactating
- •Patients not capable to understand or be compliant with the study
研究组 & 干预措施
Budesonide, 9mg, oral use
Experimental
Budesonide, 9mg, oral use, once daily, 30 minutes before meal
干预措施: budesonide (Drug)
Mannitol, 9mg, oral use
Placebo Comparator
Mannitol, 9mg, oral use, once daily, 30 minutes before meal
干预措施: Mannitol (Drug)
结局指标
主要结局
Effect of Budesonide on the reduction of the number of eosinophils on duodenal biopsies in patients with functional dyspepsia
时间窗: before treatment and 8 weeks after start of treatment (9 mg)
The primary endpoint is to evaluate the effect of Budesonide on duodenal eosinophilia (30% reduction) in patients with functional dyspepsia.
次要结局
- The effect of budesonide in functional dyspepsia on gastric emptying time.(before treatment and 8 weeks after start of treatment (9 mg))
- The effect of budesonide in functional dyspepsia on symptom outcome using the Leuven Postprandial Distress Scale (range 0-4; 0 = no symptoms, 4 = very severe symptoms)(Daily for 2 weeks before start of treatment. Daily during the 8 weeks of treatment (at 9 mg). Daily during the 4 weeks of tapering the treatment)
- The effect of budesonide in functional dyspepsia on Quality of life of patients(At baseline, 8 weeks after start of treatment (9mg), 2 weeks after start of tapering (which is at 10 weeks), at the end of tapering (at 12 weeks), at 16 weeks (4 weeks after treatment discontinuation))
- The effect of budesonide in functional dyspepsia on state of anxiety(At baseline, 8 weeks after start of treatment (9mg), 2 weeks after start of tapering (which is at 10 weeks), at the end of tapering (at 12 weeks), at 16 weeks (4 weeks after treatment discontinuation))
- The effect of budesonide in functional dyspepsia on state of depression(At baseline, 8 weeks after start of treatment (9mg), 2 weeks after start of tapering (which is at 10 weeks), at the end of tapering (at 12 weeks), at 16 weeks (4 weeks after treatment discontinuation))
- The effect of budesonide in functional dyspepsia on state of somatization(At baseline, 8 weeks after start of treatment (9mg), 2 weeks after start of tapering (which is at 10 weeks), at the end of tapering (at 12 weeks), at 16 weeks (4 weeks after treatment discontinuation))
- The effect of budesonide in functional dyspepsia on barrier function by measuring mRNA levels of tight-junction related molecules(before treatment and 8 weeks after start of treatment (9 mg))
- The effect of budesonide in functional dyspepsia on barrier function by measuring mRNA levels of pro-inflammatory cytokines(before treatment and 8 weeks after start of treatment (9 mg))
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Budesonide as a treatment for inflammation in stomach complaints.Functional dyspepsiaEUCTR2020-002593-27-BEZ Leuven36
已完成
3 期
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisProctosigmoiditisProctitisNCT01008423Bausch Health Americas, Inc.281
已完成
3 期
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisProctitisProctosigmoiditisNCT01008410Bausch Health Americas, Inc.265
已完成
1 期
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and FormoterolChronic Obstructive Pulmonary Disease (COPD)NCT04600505AstraZeneca47
招募中
2 期
GVHD-budesonide trialJPRN-jRCTs021210039Yamashita Takaya20